Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01408
|
|||||
| Drug Name |
Ciclesonide
|
|||||
| Synonyms |
Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Asthma [ICD11:CA23] | Approved | [1] | |||
| Therapeutic Class |
Antiallergic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C32H44O7
|
|||||
| Canonical SMILES |
CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
|
|||||
| InChI |
InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
|
|||||
| InChIKey |
LUKZNWIVRBCLON-GXOBDPJESA-N
|
|||||
| CAS Number |
CAS 141845-82-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 540.7 | Topological Polar Surface Area | 99.1 | ||
| Heavy Atom Count | 39 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
5.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
7848766
,12014485
,14763472
,14910303
,17194708
,43529548
,50069804
,50113016
,53790514
,57371818
,75476862
,92719025
,93307925
,93815124
,126592968
,126621149
,126652709
,135211289
,135805250
,137002365
,137619495
,144206039
,152134121
,160668474
,162183036
,162258877
,164788141
,175266964
,184545966
,187051772
,187072300
,196106072
,210279779
,210282102
,223657022
,224423934
,226395815
,251915931
,251917279
,252215142
,252347327
|
|||||
| ChEBI ID |
CHEBI:31397
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ciclesonide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.